REG - Anheuser-Busch InBev - Publication of Suppl.Prospcts

Anheuser-Busch Inbev SAAnnouncement

24/03/2020 13:55

RNS Number : 4067H
  
Anheuser-Busch InBev SA/NV
  
24 March 2020
  
 

Anheuser-Busch InBev SA/NV
24 March 2020
Publication of Base Prospectus
The following base prospectus supplement (the "Base Prospectus Supplement") has been approved by the UK Listing Authority and is available for viewing: 
Supplement Number 1 dated 24 March 2020

to the Base Prospectus dated 13 December 2019 relating to the
Anheuser-Busch InBev SA/NV
€40,000,000,000 Euro Medium Term Note Programme
unconditionally and irrevocably guaranteed by
Anheuser-Busch  Companies,  LLC, Anheuser-Busch Inbev Finance Inc., Anheuser-Busch Inbev Worldwide Inc., Brandbev S.à r.l., Brandbrew  S.A. and Cobrew NV
Please read the disclaimer below "Disclaimer - Intended Addressees" before attempting to access this service, as your right to do so is conditional upon complying with the requirements set out below.
To view the full document, please paste the following URL into the address bar of your browser:
http://www.rns-pdf.londonstockexchange.com/rns/4067H_1-2020-3-24.pdf
A copy of the Base Prospectus Supplement will be submitted to the National Storage Mechanism and will shortly be available for inspection at: www.morningstar.co.uk/uk/NSM.
For further information, please contact:
 




Lauren Abbott
Tel: +1 212 573 9287
E-mail: lauren.abbott@ab-inbev.com
 
or
 




Mariusz Glukhova
Tel: +32 16 276 888
E-mail: mariusz.glukhova@ab-inbev.com
 
or
 




Jency John
Tel: +1 646 746 9673
Email: jency.john@ab-inbev.com
 




Anheuser-Busch InBev SA/NV
Brouwerijplein 1, 3000 Leuven, Belgium  
This announcement does not constitute or form part of an offer to sell or the solicitation of an offer to subscribe for or otherwise acquire any securities.
DISCLAIMER - INTENDED ADDRESSEES 
Please note that the information contained in the Base Prospectus may be addressed to and/or targeted at persons who are residents of particular countries (specified in the Base Prospectus) only and is not intended for use and should not be relied upon by any person outside these countries and/or to whom the offer contained in the Base Prospectus is not addressed. Prior to relying on the information contained in the Base Prospectus you must ascertain from the Base Prospectus whether or not you are part of the intended addressees of, and eligible to view, the information contained therein.
In particular, neither this announcement nor the Base Prospectus shall constitute an offer to sell or the solicitation of an offer to buy securities in the United States or in any other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration, exemption from registration or qualification under the securities law of any such jurisdiction.
The securities described in the Base Prospectus (the "Securities") have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), or under any relevant securities laws of any state of the United States of America and are subject to U.S. tax law requirements. Subject to certain exceptions, the Securities may not be offered or sold directly or indirectly within the United States or to, or for the account or benefit of, U.S. persons or to persons within the United States of America, as such terms are defined in Regulation S under the Securities Act.  Any forwarding, distribution or reproduction of the Base Prospectus in whole or in part is prohibited. Failure to comply with this notice may result in a violation of the Securities Act or the applicable laws of other jurisdictions. There will be no public offering of the Securities in the United States.
Your right to access this service is conditional upon complying with the above requirement.


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
  END
 
 
PSPEADDLASFEEFA